Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Trial of Autologous T Cells Engineered to Express NY-ESO-1 TCR and CRISPR Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T Cells)

Next Previous
Trial Profile

Phase 1 Trial of Autologous T Cells Engineered to Express NY-ESO-1 TCR and CRISPR Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T Cells)

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NY-ESO-1 TCR-T cell therapy (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Malignant melanoma; Multiple myeloma; Myxoid liposarcoma; Synovial sarcoma
  • Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

  • 05 May 2020 According to Clinicaltrials.gov the sponsor has terminated trial to pursue other targets.
  • 05 May 2020 Status changed from active, no longer recruiting to discontinued.
  • 03 Jan 2020 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top